Abstract
Preoperative chemotherapy for potentially resectable colorectal liver metastases can lead to the disappearance of up to 25% of lesions on cross-sectional imaging, a phenomenon termed “disappearing liver metastasis” (DLM). While radiologic response from preoperative therapy can be seen as a desirable outcome, DLM can be a management challenge for the hepatic surgeon. Specifically, even when a metastasis “disappears,” viable malignancy remains present in up to 80% of cases. Therefore, all initially identified macroscopic disease should be resected or ablated if a curative intent strategy is being considered. Patients with smaller lesions and those deep within the hepatic parenchyma, as well as those who receive a longer duration of preoperative therapy, are at higher risk for DLM development. Early multidisciplinary case discussion of involving the hepatic surgeon is crucial to limit this conundrum. High-quality contrast-enhanced imaging prior to initiation of chemotherapy is important in order to identify all disease. Limiting the duration of chemotherapy can be useful particularly when lesions are small and when sub-lobar resections or ablations are anticipated. In some cases with small tumors which are initially resectable, proceeding directly to surgery rather than using neoadjuvant chemotherapy should be considered. While many DLM can be identified intraoperatively with a thorough examination and intraoperative ultrasonography, an attempt to treat all original sites of disease should be made, when possible. When not achievable and occult sites are left behind, these can often be followed and managed upon recurrence with a staged approach.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240(4):644–57; discussion 57–8.
Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007–16.
Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208–15.
Adam R, Wicherts DA, de Haas RJ, Aloia T, Levi F, Paule B, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol. 2008;26(10):1635–41.
Blazer DG 3rd, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26(33):5344–51.
Chun YS, Vauthey J-N, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009;302(19952320):2338–44.
de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997;15(2):808–15.
Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041–7.
Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229–37.
Dy GK, Krook JE, Green EM, Sargent DJ, Delaunoit T, Morton RF, et al. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. J Clin Oncol. 2007;25(23):3469–74.
Elias D, Youssef O, Sideris L, Dromain C, Baton O, Boige V, et al. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol. 2004;86(1):4–9.
Benoist S, Brouquet A, Penna C, Julie C, El Hajjam M, Chagnon S, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006;24(24):3939–45.
Elias D, Goere D, Boige V, Kohneh-Sharhi N, Malka D, Tomasic G, et al. Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol. 2007;14(11):3188–94.
Tanaka K, Takakura H, Takeda K, Matsuo K, Nagano Y, Endo I. Importance of complete pathologic response to prehepatectomy chemotherapy in treating colorectal cancer metastases. Ann Surg. 2009;250(6):935–42.
Auer RC, White RR, Kemeny NE, Schwartz LH, Shia J, Blumgart LH, et al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer. 2010;116(6):1502–9.
van Vledder MG, de Jong MC, Pawlik TM, Schulick RD, Diaz LA, Choti MA. Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J Gastrointest Surg. 2010;14(11):1691–700.
Ferrero A, Langella S, Russolillo N, Vigano L, Lo Tesoriere R, Capussotti L. Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease. J Gastrointest Surg. 2012;16(4):806–14.
Ono T, Ishida H, Kumamoto K, Okada N, Ishibashi K. Outcome in disappearing colorectal cancer liver metastases during oxaliplatin-based chemotherapy. Oncol Lett. 2012;4(5):905–9.
Robinson PJ. The effects of cancer chemotherapy on liver imaging. Eur Radiol. 2009;19(7):1752–62.
van Vledder MG, Torbenson MS, Pawlik TM, Boctor EM, Hamper UM, Olino K, et al. The effect of steatosis on echogenicity of colorectal liver metastases on intraoperative ultrasonography. Arch Surg. 2010;145(7):661–7.
Takahashi M, Hasegawa K, Arita J, Hata S, Aoki T, Sakamoto Y, et al. Contrast-enhanced intraoperative ultrasonography using perfluorobutane microbubbles for the enumeration of colorectal liver metastases. Br J Surg. 2012;99(9):1271–7.
Arita J, Ono Y, Takahashi M, Inoue Y, Takahashi Y, Saiura A. Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy. Ann Surg Oncol. 2014;21 Suppl 3:S390–7.
Sturesson C, Nilsson J, Lindell G, Andersson RG, Keussen I. Disappearing liver metastases from colorectal cancer: impact of modern imaging modalities. HPB (Oxford). 2015;17(11):983–7.
Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243(1):1–7.
Kishi Y, Zorzi D, Contreras CM, Maru DM, Kopetz S, Ribero D, et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2010;17(11):2870–6.
Zalinski S, Abdalla EK, Mahvash A, Vauthey JN. A marking technique for intraoperative localization of small liver metastases before systemic chemotherapy. Ann Surg Oncol. 2009;16(5):1208–11.
Passot G, Odisio BC, Zorzi D, Mahvash A, Gupta S, Wallace MJ, et al. Eradication of missing liver metastases after fiducial placement. J Gastrointest Surg. 2016;20(6):1173–8.
Kuszyk BS, Bluemke DA, Urban BA, Choti MA, Hruban RH, Sitzmann JV, et al. Portal-phase contrast-enhanced helical CT for the detection of malignant hepatic tumors: sensitivity based on comparison with intraoperative and pathologic findings. AJR Am J Roentgenol. 1996;166(1):91–5.
Kamel IR, Choti MA, Horton KM, Braga HJ, Birnbaum BA, Fishman EK, et al. Surgically staged focal liver lesions: accuracy and reproducibility of dual-phase helical CT for detection and characterization. Radiology. 2003;227(3):752–7.
Kondo H, Kanematsu M, Hoshi H, Murakami T, Kim T, Hori M, et al. Preoperative detection of malignant hepatic tumors: comparison of combined methods of MR imaging with combined methods of CT. AJR Am J Roentgenol. 2000;174(4):947–54.
Bhattacharjya S, Bhattacharjya T, Baber S, Tibballs JM, Watkinson AF, Davidson BR. Prospective study of contrast-enhanced computed tomography, computed tomography during arterioportography, and magnetic resonance imaging for staging colorectal liver metastases for liver resection. Br J Surg. 2004;91(10):1361–9.
Fong Y, Saldinger PF, Akhurst T, Macapinlac H, Yeung H, Finn RD, et al. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg. 1999;178(4):282–7.
van Etten B, van der Sijp J, Kruyt R, Oudkerk M, van der Holt B, Wiggers T. Ferumoxide-enhanced magnetic resonance imaging techniques in pre-operative assessment for colorectal liver metastases. Eur J Surg Oncol. 2002;28(6):645–51.
Larson RE, Semelka RC, Bagley AS, Molina PL, Brown ED, Lee JK. Hypervascular malignant liver lesions: comparison of various MR imaging pulse sequences and dynamic CT. Radiology. 1994;192(2):393–9.
Oudkerk M, van den Heuvel AG, Wielopolski PA, Schmitz PI, Borel Rinkes IH, Wiggers T. Hepatic lesions: detection with ferumoxide-enhanced T1-weighted MR imaging. Radiology. 1997;203(2):449–56.
van Kessel CS, Buckens CF, van den Bosch MA, van Leeuwen MS, van Hillegersberg R, Verkooijen HM. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol. 2012;19(9):2805–13.
Owen JW, Fowler KJ, Doyle MB, Saad NE, Linehan DC, Chapman WC. Colorectal liver metastases: disappearing lesions in the era of Eovist hepatobiliary magnetic resonance imaging. HPB (Oxford). 2016;18(3):296–303.
Kingham TP, Scherer MA, Neese BW, Clements LW, Stefansic JD, Jarnagin WR. Image-guided liver surgery: intraoperative projection of computed tomography images utilizing tracked ultrasound. HPB (Oxford). 2012;14(9):594–603.
Disclosures
The authors have no relevant conflicts of interest to disclose.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Karagkounis, G., Choti, M.A. (2020). Management of Disappearing Liver Metastasis Following Preoperative Chemotherapy. In: Correia, M., Choti, M., Rocha, F., Wakabayashi, G. (eds) Colorectal Cancer Liver Metastases. Springer, Cham. https://doi.org/10.1007/978-3-030-25486-5_17
Download citation
DOI: https://doi.org/10.1007/978-3-030-25486-5_17
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-25485-8
Online ISBN: 978-3-030-25486-5
eBook Packages: MedicineMedicine (R0)